(decided on motions to dismiss) and Nexium and Wellbutrin
5, 2013) (alleging global settlement of patent litigation and waiver of full damage claim is payment for generic delay); In re Aggrenox
Antitrust Litig, 94 F.
The study also showed that Boehringer's blood thinner Aggrenox
combined with aspirin was no better than a top-selling competitor, Plavix, in preventing stroke recurrence.
Adapting to a new model is always a challenge, but because multiple brands, namely Spiriva HandiHaler (tiotropium bromide inhalation powder), Flomax (tamsulosin HCI) capsules 0.4 mg, Mirapex (pramipexole dihydrochloride) tablets, Aggrenox
(aspirin/extended-release dipyridamole) 25 mg/200 mg capsules, Micardis (telmisartan) tablets, and Micardis HCT (telmisartan/hydrochlorothiazide) 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg tablets, and multiple channels (commercial, federal, state, trade, senior care) needed to be considered, integrating this new model was especially complicated.
Combination aspirin and dipyridamole (Aggrenox
) therapy reduces the risk of secondary stroke.
Circumscribed skin necrosis and pseudovasculitis lesions need to be treated with antiplatelet agents such as the combination of low-dose aspirin and dipyridamole (Aggrenox
), anticoagulants, and fibrinolytic agents, she added.
A large study showed that Aggrenox
(aspirin/ extended-release dipyridamole) is significantly more effective in preventing a second stroke than aspirin.
Reddy's Laboratories Ltd (BSE: 500124) (NYSE: RDY) has launched Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox
(aspirin and extended-release dipyridamole) Capsules in the United States market following approval from the US Food and Drug Administration (USFDA), the company said.
The settlement alleges that the company misrepresented its antiplatelet drug, Aggrenox
, that was effective for many conditions 'below the neck,' such as heart attacks and congestive heart failure, and that it was superior to Plavix, without evidence to substantiate that claim; misrepresented that Micardis protected patients from early morning strokes and heart attacks and treated metabolic syndrome; misrepresented that Combivent could be used as a first-line treatment for bronchospasms associated with chronic obstructive pulmonary disease (COPD); Falsely stated that Atrovent and Combivent could be used at doses that exceeded the maximum dosage recommendation in the product labelling and that the drugs were essential for treatment of COPD.
(111.) See, e.g., In re Aggrenox
Antitrust Litig., No.